Golden Marine Biotechnologies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 9 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -22.53%
(FY 2023)
- Profit -44.38%
(FY 2023)
- Ebitda -24.77%
(FY 2023)
- Net Worth 14.45%
(FY 2023)
- Total Assets 50.38%
(FY 2023)
About Golden Marine Biotechnologies
The Corporate was formerly known as Hi - Tide Bioremedies Private Limited. The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Bhavani Korikana, Simhachalam Challa, and Nand Lathker serve as directors at the Company.
- CIN/LLPIN
U74200TG2014PTC097044
- Company No.
097044
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Dec 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rajendranagar, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Golden Marine Biotechnologies?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nand Lathker  | Managing Director | 01-Apr-2023 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Bhavani Korikana | Director | 30-Dec-2014 | Current |
| Simhachalam Challa | Whole-Time Director | 30-Dec-2014 | Current |
Financial Performance of Golden Marine Biotechnologies.
Golden Marine Biotechnologies Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 22.53% decrease. The company also saw a substantial fall in profitability, with a 44.38% decrease in profit. The company's net worth Soared by an impressive increase of 14.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Golden Marine Biotechnologies?
In 2023, Golden Marine Biotechnologies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Infini Foods India Private LimitedActive 3 years 3 monthsBhavani Korikana and Nand Lathker are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Golden Marine Biotechnologies?
Unlock and access historical data on people associated with Golden Marine Biotechnologies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Golden Marine Biotechnologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Golden Marine Biotechnologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
